PA8615301A1 - Formulaciones farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos. - Google Patents

Formulaciones farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos.

Info

Publication number
PA8615301A1
PA8615301A1 PA20048615301A PA8615301A PA8615301A1 PA 8615301 A1 PA8615301 A1 PA 8615301A1 PA 20048615301 A PA20048615301 A PA 20048615301A PA 8615301 A PA8615301 A PA 8615301A PA 8615301 A1 PA8615301 A1 PA 8615301A1
Authority
PA
Panama
Prior art keywords
methods
prevention
treatment
pharmaceutical formulations
acute coronary
Prior art date
Application number
PA20048615301A
Other languages
English (en)
Inventor
Charles L Bisgaier
Wendi V Rodrigueza
Narendra D Lalwani
Daniel Hartman
Jan Johansson
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of PA8615301A1 publication Critical patent/PA8615301A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION PROVEE METODOS Y FORMULACIONES PARA EL TRATAMIENTO Y LA PREVENCION DE LOS SINDROMES CORONARIOS AGUDOS. LOS METODOS DE ESTA INVENCION PROVEEN DOSIS SEGURAS Y EFECTIVAS DE UNA APOLIPROTEINA A-I MILANO: COMPLEJO FOSFOLIPIDO PARA REDUCIR Y ESTABILIZAR LA PLAQUETA ATEROESCLEROTICA. TAMBIEN SON PROVISTAS FORMULACIONES FARMACEUTICAS DE LA APO A-I MILANO: COMPLEJO FOSFOLIPIDOS.
PA20048615301A 2003-10-20 2004-10-20 Formulaciones farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos. PA8615301A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51311603P 2003-10-20 2003-10-20
US51701603P 2003-11-03 2003-11-03
US57112904P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
PA8615301A1 true PA8615301A1 (es) 2005-09-28

Family

ID=34557347

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048615301A PA8615301A1 (es) 2003-10-20 2004-10-20 Formulaciones farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos.

Country Status (24)

Country Link
US (2) US7435717B2 (es)
EP (1) EP1677597B1 (es)
JP (1) JP2007509157A (es)
KR (3) KR20100101710A (es)
AR (1) AR046126A1 (es)
AU (2) AU2004284932A1 (es)
CA (1) CA2542726C (es)
CO (1) CO5690611A2 (es)
CR (1) CR8352A (es)
EA (1) EA010134B1 (es)
EC (1) ECSP066516A (es)
ES (1) ES2449719T3 (es)
GE (1) GEP20094601B (es)
HK (1) HK1093869A1 (es)
IL (1) IL174301A (es)
MA (1) MA28102A1 (es)
MX (1) MXPA06004362A (es)
NO (1) NO339456B1 (es)
NZ (1) NZ545939A (es)
OA (1) OA13272A (es)
PA (1) PA8615301A1 (es)
PE (1) PE20050438A1 (es)
RS (1) RS20060273A (es)
WO (1) WO2005041866A2 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8246671B2 (en) 1999-08-09 2012-08-21 Cardiokinetix, Inc. Retrievable cardiac devices
US8257428B2 (en) 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US8388672B2 (en) 1999-08-09 2013-03-05 Cardiokinetix, Inc. System for improving cardiac function by sealing a partitioning membrane within a ventricle
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US7674222B2 (en) 1999-08-09 2010-03-09 Cardiokinetix, Inc. Cardiac device and methods of use thereof
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US9078660B2 (en) 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
PL372925A1 (en) * 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
US20040067873A1 (en) * 2002-05-17 2004-04-08 Dasseux Jean-Louis H. Method of treating dyslipidemic disorders
WO2005097206A2 (en) * 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
JP4880685B2 (ja) * 2005-07-22 2012-02-22 ザ プロクター アンド ギャンブル カンパニー 薬物による不整脈の発生を低減するための組成物
WO2007130724A2 (en) * 2006-02-06 2007-11-15 Northwind Ventures Systems and methods for volume reduction
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
AU2007224175A1 (en) * 2006-03-03 2007-09-13 Activbiotics Pharma Llc Treatment of atherosclerotic disease
DE102007006663A1 (de) * 2007-02-10 2008-08-21 Lts Lohmann Therapie-Systeme Ag Transport von Arzneistoffen über die Blut-Hirn-Schranke mittels Apolipoproteinen
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (en) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc DEVICE FOR MEASURING THE CONCENTRATION OF A SOLVED SUBSTANCE AND CORRESPONDING METHOD
US8980296B2 (en) * 2009-02-18 2015-03-17 Cormatrix Cardiovascular, Inc. Compositions and methods for preventing cardiac arrhythmia
AU2010217760B2 (en) 2009-02-27 2015-04-09 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US20100234827A1 (en) * 2009-03-13 2010-09-16 Sigg Daniel C Method of treating heart failure
US20110152770A1 (en) 2009-07-30 2011-06-23 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US8790242B2 (en) 2009-10-26 2014-07-29 Cardiokinetix, Inc. Ventricular volume reduction
AU2011274238B2 (en) 2010-06-30 2013-09-26 Csl Limited A reconstituted high density lipoprotein formulation and production method thereof
TW201215394A (en) 2010-08-30 2012-04-16 Hoffmann La Roche Tetranectin-apolipoprotein A-I, lipid particles containing it and its use
JP2013538205A (ja) 2010-08-30 2013-10-10 エフ．ホフマン−ラ ロシュ アーゲー テトラネクチン−アポリポタンパク質ａ−ｉ粒子を産生するための方法、それを用いて得られる脂質粒子、及びその使用
BR112013004397A2 (pt) 2010-08-30 2017-06-27 Hoffmann La Roche método para produzir uma partícula de lipídio, a partícula de lipídio em si e seu uso
DK2767546T3 (en) 2011-02-07 2019-02-04 Cerenis Therapeutics Holding Sa Lipoprotein complexes and their preparation and uses
AU2012249324B2 (en) * 2011-04-27 2016-10-06 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein CIII (ApoCIII) expression
WO2012162392A1 (en) 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
CA2838070A1 (en) 2011-08-25 2013-02-28 F. Hoffmann-La Roche Ag Shortened tetranectin-apolipoprotein a-i fusion protein, a lipid particle containing it, and uses thereof
RU2014129505A (ru) * 2011-12-21 2016-02-10 СиЭсЭл ЛИМИТЕД Схема дозирования для составов аполипопротеина
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
AU2014228815B2 (en) 2013-03-15 2019-04-18 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
HUE039246T2 (hu) * 2013-10-31 2018-12-28 Novo Nordisk As Injekciós készülék tûkanüllel
CA2962747C (en) 2014-09-28 2023-02-28 Cardiokinetix, Inc. Apparatuses for treating cardiac dysfunction
US10668015B2 (en) * 2015-01-20 2020-06-02 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
DK3341044T3 (da) * 2015-08-25 2020-02-17 Novo Nordisk As Medicinsk injektionsindretning med et rensningskammer
US10898330B2 (en) 2017-03-28 2021-01-26 Edwards Lifesciences Corporation Positioning, deploying, and retrieving implantable devices
JP6784973B2 (ja) * 2017-03-30 2020-11-18 国立研究開発法人産業技術総合研究所 単層カーボンナノチューブ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
US6306433B1 (en) * 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
PL372925A1 (en) * 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
US20040067873A1 (en) * 2002-05-17 2004-04-08 Dasseux Jean-Louis H. Method of treating dyslipidemic disorders
CA2485989A1 (en) * 2002-05-17 2003-11-27 Esperion Therapeutics, Inc. Methods and compositions for the treatment of ischemic reperfusion

Also Published As

Publication number Publication date
WO2005041866A3 (en) 2006-05-18
EP1677597A4 (en) 2011-08-24
KR20070110561A (ko) 2007-11-19
AR046126A1 (es) 2005-11-23
MA28102A1 (fr) 2006-08-01
EP1677597B1 (en) 2014-01-08
JP2007509157A (ja) 2007-04-12
ECSP066516A (es) 2006-11-24
EP1677597A2 (en) 2006-07-12
US7435717B2 (en) 2008-10-14
RS20060273A (sr) 2008-09-29
CO5690611A2 (es) 2006-10-31
HK1093869A1 (en) 2007-03-16
AU2011202014B2 (en) 2012-06-14
EA200600548A1 (ru) 2006-10-27
OA13272A (en) 2007-01-31
NO20062110L (no) 2006-07-18
MXPA06004362A (es) 2006-09-04
KR20060080227A (ko) 2006-07-07
GEP20094601B (en) 2009-02-10
AU2004284932A1 (en) 2005-05-12
WO2005041866A2 (en) 2005-05-12
CA2542726A1 (en) 2005-05-12
ES2449719T3 (es) 2014-03-20
CA2542726C (en) 2012-05-15
AU2011202014A1 (en) 2011-05-26
PE20050438A1 (es) 2005-06-14
NZ545939A (en) 2008-08-29
US20080293633A1 (en) 2008-11-27
IL174301A0 (en) 2006-08-01
CR8352A (es) 2007-03-02
NO339456B1 (no) 2016-12-12
EA010134B1 (ru) 2008-06-30
KR20100101710A (ko) 2010-09-17
US20050142180A1 (en) 2005-06-30
IL174301A (en) 2013-09-30

Similar Documents

Publication Publication Date Title
PA8615301A1 (es) Formulaciones farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos.
CY1116215T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
GT200300075BA (es) Compuestos que modulan la actividad ppar y procedimientos para su preparacion (patente fraccionaria no. 2 de la solicitud no. pi-20030075)
PA8592301A1 (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
DOP2009000155A (es) Derivados de hetero-pentaciclo-fenilo fusionados, composicion farmaceutica que los comprende y usos para preparar un medicamento util para el tratamiento de una condicion mediada por p38
ECSP056246A (es) DERIVADOS DE PIRROLO [3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA
CY1110013T1 (el) Συνδυασμοι για θεραπεια πολλαπλου μυελωματος
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
PA8616201A1 (es) Composiciones farmaceuticas de liberacion sostenida
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
DOP2001000294A (es) Combinación de agonistas de gaba e inhibidores de aldosa-reductasa
DOP2003000708A (es) Formulaciones que comprenden un compuesto a base de indolinona
ECSP034624A (es) Combinacion de agonista de gava e inhibidores de sorbitol-deshidrogenasa
AR060303A1 (es) Formulaciones farmaceuticas sales de 8- [1- (3,5 -bis- (trifluorometil) fenil) -etoximetil] -8-fenil-1,7 -diaza-espiro [4.5] decan -2- ona y metodos de tratamiento utilizando las mismas
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
CL2004000452A1 (es) Uso de un compuesto antiepileptico que contiene propiedades de alivio del dolor y dos o mas compuestos del grupo formado por antagonista del nmda selectivos de subtipo, analgesicos, nsaid, y combinaciones de ellos, para la preparacion de un medicamen
CO2022005926A2 (es) Inhibidores del factor d del complemento para administración oral
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
GT200500018A (es) Formulas farmaceuticas: metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos.
DOP2004001009A (es) Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
UY28569A1 (es) Fórmulas farmacéuticas, métodos y regímenes de dosificación para el tratamiento y la prevención de síndromes coronarios agudos
UY26814A1 (es) Método y composición
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
AR126702A1 (es) Compuestos fosfolípidos y métodos de preparación y uso de los mismos
AR045177A1 (es) Uso de un compuesto tazaroteno para preparar una composicion farmaceutica de utilidad para tratar acne noduloquistico severo o grave